Thursday, October 8, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 19, 2026

Defense Stock Face-Off: Lockheed Martin vs. Howmet Aerospace -- Which Is the Better Buy Right Now?

View original at nasdaq.com
Defense Stock Face-Off: Lockheed Martin vs. Howmet Aerospace -- Which Is the Better Buy Right Now? Key Points Lockheed Martin and Howmet Aerospace benefit from increased defense spending…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Howmet Aerospace is trading at more than 54 times forward earnings estimates, more than twice Lockheed's forward P/E ratio of 20.6, meaning much of Howmet's growth is already priced in

    60% confidence

  • The war in Iran will push Howmet's likely growth higher in 2026

    60% confidence

  • Lockheed Martin's position as lead contractor for F-35 and major missile programs ensures steady cash flow largely insulated from traditional economic recessions

    60% confidence

  • Lockheed Martin is a better buy than Howmet Aerospace due to steady income production, huge backlog, and greater diversity

    60% confidence

  • The Motley Fool Stock Advisor identified 10 best stocks for investors to buy now, and Lockheed Martin was not one of them

    60% confidence

Data points we hold from this source

Lockheed Martin Corporation · forward pe ratio20.6 ratio
Lockheed Martin Corporation · backlog194 USD
Lockheed Martin Corporation · quarterly dividend3.45 USD
Lockheed Martin Corporation · eps21.49 USD
Lockheed Martin Corporation · consecutive dividend increases23 years
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com
Defense Stock Face-Off: Lockheed Martin vs. Howmet Aerospace -- Which Is the Better Buy Right Now? — Source | Via News | ViaNews Market